Conversion of Tuberculosis Screening Tests During Biologic Therapy Among Veteran Patient Population With Rheumatic Disease
Objective The optimal strategy to detect the development of tuberculosis (TB) in subjects receiving biologic agents is not clear. The recommendations vary because there is wide variation in the reported rate of seroconversion in various parts of the world. There is a scarcity of long‐term studies re...
| Main Authors: | , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2019-11-01
|
| Series: | ACR Open Rheumatology |
| Online Access: | https://doi.org/10.1002/acr2.11070 |
| _version_ | 1819178959569420288 |
|---|---|
| author | Debendra Pattanaik Sandeep Gupta Syed Islam Kunal Singhal Syed Raza |
| author_facet | Debendra Pattanaik Sandeep Gupta Syed Islam Kunal Singhal Syed Raza |
| author_sort | Debendra Pattanaik |
| collection | DOAJ |
| description | Objective The optimal strategy to detect the development of tuberculosis (TB) in subjects receiving biologic agents is not clear. The recommendations vary because there is wide variation in the reported rate of seroconversion in various parts of the world. There is a scarcity of long‐term studies regarding seroconversion of TB in the United States among these patients. Methods This is a retrospective study among veteran populations with rheumatic diseases who received various biologic agents between 2003 and 2014. Subjects who had repeated TB screening tests and adequate follow‐up periods were considered for the study. Results Out of 298 subjects who received biologic agents, 123 were considered for the study. After the initial negative screening test by tuberculin skin test (TST), patients were screened on an average of 1.2 years for 4.3 to 12 years. A total of 420 tests were performed, which were combination of TST and QuantiFERON‐TB gold in‐Tube assay. Only 1 out of 123 subjects (0.8%) seroconverted to latent TB and was treated with isoniazid for 9 months. Conclusion Our results are in line with a few other studies reported from the United States. We conclude that in areas with low prevalence of TB the seroconversion rate is extremely low and annual testing is unnecessary in low‐risk patient populations. |
| first_indexed | 2024-12-22T21:50:50Z |
| format | Article |
| id | doaj.art-43920d393b5d4c3c8b513c8835644f50 |
| institution | Directory Open Access Journal |
| issn | 2578-5745 |
| language | English |
| last_indexed | 2024-12-22T21:50:50Z |
| publishDate | 2019-11-01 |
| publisher | Wiley |
| record_format | Article |
| series | ACR Open Rheumatology |
| spelling | doaj.art-43920d393b5d4c3c8b513c8835644f502022-12-21T18:11:22ZengWileyACR Open Rheumatology2578-57452019-11-011954254510.1002/acr2.11070Conversion of Tuberculosis Screening Tests During Biologic Therapy Among Veteran Patient Population With Rheumatic DiseaseDebendra Pattanaik0Sandeep Gupta1Syed Islam2Kunal Singhal3Syed Raza4University of Tennessee Health Science Center Memphis TennesseeUniversity of Tennessee Health Science Center Memphis TennesseeUniversity of Tennessee Health Science Center Memphis TennesseeUniversity of Tennessee Health Science Center Memphis TennesseeUniversity of Tennessee Health Science Center Memphis TennesseeObjective The optimal strategy to detect the development of tuberculosis (TB) in subjects receiving biologic agents is not clear. The recommendations vary because there is wide variation in the reported rate of seroconversion in various parts of the world. There is a scarcity of long‐term studies regarding seroconversion of TB in the United States among these patients. Methods This is a retrospective study among veteran populations with rheumatic diseases who received various biologic agents between 2003 and 2014. Subjects who had repeated TB screening tests and adequate follow‐up periods were considered for the study. Results Out of 298 subjects who received biologic agents, 123 were considered for the study. After the initial negative screening test by tuberculin skin test (TST), patients were screened on an average of 1.2 years for 4.3 to 12 years. A total of 420 tests were performed, which were combination of TST and QuantiFERON‐TB gold in‐Tube assay. Only 1 out of 123 subjects (0.8%) seroconverted to latent TB and was treated with isoniazid for 9 months. Conclusion Our results are in line with a few other studies reported from the United States. We conclude that in areas with low prevalence of TB the seroconversion rate is extremely low and annual testing is unnecessary in low‐risk patient populations.https://doi.org/10.1002/acr2.11070 |
| spellingShingle | Debendra Pattanaik Sandeep Gupta Syed Islam Kunal Singhal Syed Raza Conversion of Tuberculosis Screening Tests During Biologic Therapy Among Veteran Patient Population With Rheumatic Disease ACR Open Rheumatology |
| title | Conversion of Tuberculosis Screening Tests During Biologic Therapy Among Veteran Patient Population With Rheumatic Disease |
| title_full | Conversion of Tuberculosis Screening Tests During Biologic Therapy Among Veteran Patient Population With Rheumatic Disease |
| title_fullStr | Conversion of Tuberculosis Screening Tests During Biologic Therapy Among Veteran Patient Population With Rheumatic Disease |
| title_full_unstemmed | Conversion of Tuberculosis Screening Tests During Biologic Therapy Among Veteran Patient Population With Rheumatic Disease |
| title_short | Conversion of Tuberculosis Screening Tests During Biologic Therapy Among Veteran Patient Population With Rheumatic Disease |
| title_sort | conversion of tuberculosis screening tests during biologic therapy among veteran patient population with rheumatic disease |
| url | https://doi.org/10.1002/acr2.11070 |
| work_keys_str_mv | AT debendrapattanaik conversionoftuberculosisscreeningtestsduringbiologictherapyamongveteranpatientpopulationwithrheumaticdisease AT sandeepgupta conversionoftuberculosisscreeningtestsduringbiologictherapyamongveteranpatientpopulationwithrheumaticdisease AT syedislam conversionoftuberculosisscreeningtestsduringbiologictherapyamongveteranpatientpopulationwithrheumaticdisease AT kunalsinghal conversionoftuberculosisscreeningtestsduringbiologictherapyamongveteranpatientpopulationwithrheumaticdisease AT syedraza conversionoftuberculosisscreeningtestsduringbiologictherapyamongveteranpatientpopulationwithrheumaticdisease |